New Research


Neuro Bio aims to develop a treatment for Alzheimer's Disease

Susan Greenfield's company has announced a new investment, which will enable them to carry out important research that could improve millions of lives around the world. Neuro-Bio Ltd, a biopharmaceutical company focussing on neurodegenerative diseases, today announced it has received Series A funding of $3.2 million from US-based Kairos Ventures. The investment was to continue developing a diagnostic tool for early detection of Alzheimer’s and to discover new drugs targeting the disease. The new investment will allow Neuro-Bio to develop the biomarker into a diagnostic tool and to make substantive progress towards identifying a lead compound with promising therapeutic potential in Alzheimer’s disease.

The company is located on the Culham Science Park, Oxfordshire and was founded in 2013 by Baroness Professor Susan Greenfield based on 40 years of original neuroscience research leading to an exclusive and proprietary approach to developing a new solution to arrest the progress of these CNS disorders.

Alzheimer’s disease is fast becoming one of the biggest socioeconomic burdens in the world with a growing worldwide incidence rate of almost 10 million new cases each year. Since both the incidence and prevalence of Alzheimer’s disease increases with age, the number of patients is growing significantly with an aging population, as stated in Susan Greenfield video here. Alzheimer’s disease was recently announced as the UK’s leading cause of death in the over 65’s and in the US it is now the 6th leading cause of death across all ages and so this new research comes as welcome news.

For further information about Baroness Susan Greenfield, you can watch this video about Susan Greenfield here:

If you are interested in neuroscience and how the brain works, buy Susan Greenfield latest book on Amazon here.

You Might Also Like